Autologous mesenchymal stem cell therapy - EHL Bio

Drug Profile

Autologous mesenchymal stem cell therapy - EHL Bio

Alternative Names: ADSTEM injection

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EHL Bio
  • Class Antineoplastics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Atopic dermatitis

Most Recent Events

  • 01 Dec 2017 EHL Bio completes a phase I trial in Atopic dermatitis in South Korea (IV) (NCT02888704)
  • 19 Sep 2017 EHL Bio initiates enrolment in an observational study for Atopic dermatitis in South Korea (NCT03252340)
  • 01 Jul 2016 Phase-I clinical trials in Atopic dermatitis in South Korea (IV) (NCT02888704)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top